Financings in Brief: Sonus Pharmaceuticals
This article was originally published in The Gray Sheet
Sonus Pharmaceuticals: Commences initial public offering of 2.85 mil. shares to be sold at a price of $7 per share. Bothell, Washington-based Sonus previously expected to offer 2.5 mil. shares for $10 to $12 each ("The Gray Sheet" Oct. 2, p. 15). Underwriters Hambrecht & Quist, Montgomery Securities, and UBS Securities retain an over-allotment option to purchase up to 427,500 additional shares...
You may also be interested in...
Australian patients with phototoxicity due to the rare condition EPP will now have their first treatment option – provided the drug's developer, Clinuvel, secures reimbursement under the Pharmaceutical Benefits Scheme.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
Resilience has raised $800m to develop new technologies to manufacture complex drugs including vaccines, cell therapies and gene therapies.